Hims & Hers rolls out weight-loss shots much cheaper than Ozempic, Wegovy [FOX Business Network]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: FOX Business Network
Health platform Hims & Hers Health Inc. announced Monday that it's rolling out injectable weight-loss drugs that cost a fraction of the price of competitors Wegovy and Ozempic. Hims & Hers says its GLP-1 medications contain the same active ingredients as its rivals, but the price starts at $199 per month. For comparison, Wegovy costs around $1,350 per month, and Ozempic is priced at around $935 without insurance . Novo Nordisk produces both drugs. "We've leveraged our size and scale to secure access to one of the highest-quality supplies of compounded GLP-1 injections available today," Hims & Hers co-founder and CEO Andrew Dudum said in a statement announcing the new drugs. "We're passing that access and value along to our customers, who deserve the highest standard of clinical safety and efficacy to meet their goals, and we're doing it in a safe, affordable way that others can't deliver." Hims & Hers stock surged more than 27% to a three-year high following the news. Ticker
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health, Inc. (NYSE: HIMS) had its price target raised by analysts at Bank of America Co. from $22.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
- Hims & Hers Health, Inc. (NYSE: HIMS) had its price target raised by analysts at Bank of America Co. from $17.25 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Hims & Hers Health Stock Soared This Week: Here's Why [Yahoo! Finance]Yahoo! Finance
- The Ultimate Growth Stock to Buy With $20 Right Now [Yahoo! Finance]Yahoo! Finance
- Reasons to Include Alcon (ALC) in Your Portfolio Right Now [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 5/6/24 - Beat
HIMS
Sec Filings
- 6/13/24 - Form 144
- 6/12/24 - Form 4
- 6/12/24 - Form 4
- HIMS's page on the SEC website